TOTAL: $40.39M | ||||
Year to Date: $409.67M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
Acrux Ltd. |
Elanco Animal Health (unit of Eli Lilly and Co.) |
A$0.5 ($0.39) |
Milestone payment |
Triggered by the the granting of a patent in Europe covering Acrux's drug delivery technology; Elanco has rights in animal health applications (5/8) |
Arena |
Merck & Co. Inc. |
$4 |
Milestone payment |
Triggered by Merck's initiation of a Phase II trial of MK-0354, an Arena- discovered candi-date being developed for treating atherosclerosis and related disorders (5/18) |
Emisphere |
Novartis Pharma AG (Switzerland) |
$5 |
Milestone payment |
Triggered by Novartis' decision to initiate development of an oral human growth hormone product using Emisphere's eligen delivery technology (5/1) |
Flamel |
GlaxoSmithKline plc (UK) |
$1 |
Milestone payment |
Triggered by successful completion of activities related to the manufacturing process for Coreg CR microparticles, under their December 2004 supply agreement (5/19) |
Maxygen Inc. |
F. Hoffmann-La Roche Ltd. (Switzerland) |
$5 |
Milestone payment |
The preclinical milestone was triggered by Maxygen's development of a manufacturing process for Factor VIIa product candidates (5/9) |
Metabolex |
Astellas Pharma Inc. (Japan) |
ND |
Milestone payments |
Payments were triggered by Astellas' initiation of a high-throughput screen on a previously selected target from their collaboration, and its choice of an additional target for screening (5/25) |
Rigel |
Pfizer Inc. |
$5 |
Milestone payment |
Triggered by Pfizer's selection of R343 for advanced preclinical development in allergic asthma, from their 2005 collaboration on syk kinase inhibitors (5/17) |
SuperGen |
MGI Pharma Inc. (MOGN) |
$20 |
Milestone payment |
Triggered by MGI's first commercial shipment of the recently approved drug Dacogen (5/26) |
TransPharma- |
Teva Pharmaceuticals Industries Ltd. (Israel) |
ND |
Milestone payment |
Triggered by successful completion of the first clinical trials from their deal dating back to 2004 (5/1) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
ASX = Australian Stock Exchange. |